人附睾蛋白4在卵巢癌诊断中应用研究  

Application of human epididymis protein 4 in diagnosis of ovarian carcinoma

作　　者：贾志凌[1] 赵满仓[1] 王莉[2] 刘畅[2] 柴丽娜[1] 

机构地区：[1]北京军区总医院检验科,北京市100700 [2]北京军区总医院肿瘤科,北京市100700

出　　处：《中华实用诊断与治疗杂志》2013年第2期153-154,共2页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的探讨人附睾蛋白4(human epididymis protein 4,HE4)在卵巢癌诊断中的价值。方法采用ELISA法检测62例卵巢癌患者(卵巢癌组)、38例卵巢良性肿瘤患者(卵巢良性肿瘤组)及100例体检健康者(对照组)血清HE4水平,并与CA125试剂盒检测结果进行比较分析。结果卵巢癌组血清HE4水平((443.33±244.59)pmol/L)明显高于卵巢良性肿瘤组((113.18±79.95)pmol/L)和对照组((72.52±42.45)pmol/L),差异均有统计学意义(P<0.01);HE4诊断卵巢癌较CA125有更高的敏感度和特异性,且二者一致性较好(Kappa=0.708),HE4和CA125联合检测的敏感度和特异性分别为91.94%和92.03%,较单一标志物的检测更具优势。结论血清中HE4水平对卵巢癌具有较高诊断价值,是诊断卵巢癌新的血清标志物之一。Objective To discuss the diagnostic value of human epididymis protein 4. （HE4） level to ovarian carcinoma o{ gynecology. Methods The HE4 level was detected with ELISA technique in 62 cases of pelvic ovarian cancer （ovarian carcinoma group）, 38 cases of benign ovarian tumors （benign ovarian tumor group）, and 100 cases of healthy women （control group）, which was compared with the result of CA125 kit. Results The serum HE4 level was significantly higher in ovarian carcinoma group （（443. 33 ± 244. 59）pmol/L） than that in ovarian benign tumor group （（113. 18 ± 79.95）pmol/L） and control group （（72.52±42.45）pmol/L） （P〈0.01）. HE4 had higher sensitivity and specificity than CA125, and also had good agreement with CA125 （Kappa 0. 708）. With 91. 94% of sensitivity and 92. 03% of specificity, the joint detection of HE4 and CA125 was more superior to the single detection of HE4 or CA125. Conclusion Being one of new markers of the diagnosis of ovarian cancer, HE4 level has a high diagnostic value to ovarian carcinoma.

关 键 词：卵巢癌 人附睾蛋白4 诊断 应用 

分 类 号：R737.31[医药卫生—肿瘤]